Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ABS sticking point

By releasing its second guidance for anti-infectives within a month, FDA last week made good on its obligation to provide clarity on the requirements for drugs intended to treat acute bacterial sinusitis. But by layering a new recommendation for the use of sinus puncture and aspiration on top of the expected requirement for placebo-controlled or superiority trials, critics say the draft guidelines may have set the bar impractically high.

The guidance gives four options for trial design that may make patient recruitment less difficult than an outright requirement for placebo controls, and gives what the agency says is a viable approach for comparing the test drug to an active comparator (see BioCentury Sept. 18, 2006, Oct. 30, 2006, & Oct. 29, 2007).

The first option is for placebo-controlled studies with

Read the full 1290 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE